利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.038 秒)

    Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis
    8.
    发明授权
    Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis 有权
    包含来自LGTB脑膜炎奈瑟球菌的L2和/或L3免疫型脂寡糖的疫苗组合物

    公开(公告)号：US08221770B2

    公开(公告)日：2012-07-17

    申请号：US12909621

    申请日：2010-10-21

    申请人： Ralph Biemans ,  Philippe Denoel ,  Christiane Feron ,  Carine Goraj ,  Jan Poolman ,  Vincent Weynants

    发明人： Ralph Biemans ,  Philippe Denoel ,  Christiane Feron ,  Carine Goraj ,  Jan Poolman ,  Vincent Weynants

    IPC分类号： A61K39/05

    CPC分类号： A61K39/095 ,  A61K39/102 ,  A61K39/1045 ,  A61K2039/521 ,  A61K2039/55505 ,  A61K2039/55516 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/70 ,  C07K14/22 ,  Y02A50/396

    摘要： The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB− is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions. Bleb vaccines derived from lgtB− and capsular polysaccharide deficient meningococcal mutants are further described; as are advantageous methods of making bleb preparations where LOS is to be retained as an important antigen.

    摘要翻译： 本发明涉及奈瑟氏球菌疫苗组合物的领域，它们的制造以及这些组合物在医药中的应用。 更具体地说，本发明涉及制备新型工程化脑膜炎球菌菌株的方法，其更适合于产生奈司菌素，特别是脑膜炎球菌，外膜囊泡（或气泡）疫苗。 还基于使用已经变得更安全和/或更有效地用于人类受试者的新型LOS亚单位或脑膜炎球菌外膜囊泡（或泡沫）疫苗来描述有利的方法和疫苗产品。 描述了基因下调的组合，例如PorA和OpA，PorA和OpC，OpA和OpC，以及PorA和OpA和OpC。 或者或另外，lgtB-被证明是用于在奈瑟氏球菌疫苗组合物中有效和安全地使用L3和/或L2 LOS的最佳突变。 进一步描述衍生自lgtB-和荚膜多糖缺乏脑膜炎球菌突变体的Bleb疫苗; 制备其中保留LOS作为重要抗原的泡制剂的有利方法也是如此。

    VACCINE COMPOSITIONS COMPRISING L2 AND/OR L3 IMMUNOTYPE LIPOOLIGOSACCHARIDES FROM LGTB-NEISSERIA MENINGITIDIS
    9.
    发明申请
    VACCINE COMPOSITIONS COMPRISING L2 AND/OR L3 IMMUNOTYPE LIPOOLIGOSACCHARIDES FROM LGTB-NEISSERIA MENINGITIDIS 有权
    包含来自LGTB-NEISSERIA MENINGITIDIS的L2和/或L3免疫球蛋白胆碱酯酶的疫苗组合物

    公开(公告)号：US20110033500A1

    公开(公告)日：2011-02-10

    申请号：US12909621

    申请日：2010-10-21

    申请人： Ralph Biemans ,  Philippe Denoel ,  Christiane Feron ,  Carine Goraj ,  Jan Poolman ,  Vincent Weynants

    发明人： Ralph Biemans ,  Philippe Denoel ,  Christiane Feron ,  Carine Goraj ,  Jan Poolman ,  Vincent Weynants

    IPC分类号： A61K39/095 ,  A61K39/102 ,  A61P37/00 ,  A61P31/04 ,  C12N1/20 ,  C12N1/21 ,  A61K35/74

    CPC分类号： A61K39/095 ,  A61K39/102 ,  A61K39/1045 ,  A61K2039/521 ,  A61K2039/55505 ,  A61K2039/55516 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/70 ,  C07K14/22 ,  Y02A50/396

    摘要： The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB− is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions. Bleb vaccines derived from lgtB− and capsular polysaccharide deficient meningococcal mutants are further described; as are advantageous methods of making bleb preparations where LOS is to be retained as an important antigen.

    摘要翻译： 本发明涉及奈瑟氏球菌疫苗组合物的领域，它们的制造以及这些组合物在医药中的用途。 更具体地说，本发明涉及制备新型工程化脑膜炎球菌菌株的方法，其更适合于产生奈司菌素，特别是脑膜炎球菌，外膜囊泡（或气泡）疫苗。 还基于使用已经变得更安全和/或更有效地用于人类受试者的新型LOS亚单位或脑膜炎球菌外膜囊泡（或泡沫）疫苗来描述有利的方法和疫苗产品。 描述了基因下调的组合，例如PorA和OpA，PorA和OpC，OpA和OpC，以及PorA和OpA和OpC。 或者或另外，lgtB-被证明是用于在奈瑟氏球菌疫苗组合物中有效和安全地使用L3和/或L2 LOS的最佳突变。 进一步描述衍生自lgtB-和荚膜多糖缺乏脑膜炎球菌突变体的Bleb疫苗; 制备其中保留LOS作为重要抗原的泡制剂的有利方法也是如此。

    Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB- Neisseria meningitidis
    10.
    发明授权
    Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB- Neisseria meningitidis 有权
    包含来自LGTB-脑膜炎奈瑟氏球菌的L2和/或L3免疫型脂寡糖的疫苗组合物

    公开(公告)号：US07838014B2

    公开(公告)日：2010-11-23

    申请号：US10523044

    申请日：2003-07-31

    申请人： Ralph Biemans ,  Philippe Denoel ,  Christiane Feron ,  Carine Goraj ,  Jan Poolman ,  Vincent Weynants

    发明人： Ralph Biemans ,  Philippe Denoel ,  Christiane Feron ,  Carine Goraj ,  Jan Poolman ,  Vincent Weynants

    IPC分类号： A61K39/05

    CPC分类号： A61K39/095 ,  A61K39/102 ,  A61K39/1045 ,  A61K2039/521 ,  A61K2039/55505 ,  A61K2039/55516 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/70 ,  C07K14/22 ,  Y02A50/396

    摘要： The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and Opc, and PorA and OpA and OpC. Alternatively, or in addition, lgtB− is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions. Bleb vaccines derived from lgtB− and capsular polysaccharide deficient meningococcal mutants are further described; as are advantageous methods of making bleb preparations where LOS is to be retained as an important antigen.

    摘要翻译： 本发明涉及奈瑟氏球菌疫苗组合物的领域，它们的制造以及这些组合物在医药中的用途。 更具体地说，本发明涉及制备新型工程化脑膜炎球菌菌株的方法，其更适合于产生奈司菌素，特别是脑膜炎球菌，外膜囊泡（或气泡）疫苗。 还基于使用已经变得更安全和/或更有效地用于人类受试者的新型LOS亚单位或脑膜炎球菌外膜囊泡（或泡沫）疫苗来描述有利的方法和疫苗产品。 描述了基因下调的组合，例如PorA和OpA，PorA和OpC，OpA和Opc，以及PorA和OpA和OpC。 或者或另外，lgtB-被证明是用于在奈瑟氏球菌疫苗组合物中有效和安全地使用L3和/或L2 LOS的最佳突变。 进一步描述衍生自lgtB-和荚膜多糖缺乏脑膜炎球菌突变体的Bleb疫苗; 制备其中保留LOS作为重要抗原的泡制剂的有利方法也是如此。